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that systolic dysfunction is common in DHF. Methods: Echocardiography with tissue Dop- 
pler imaging was performed in 339 subjects, in whom 92 had systolic heart failure (SHF) 
(ejection fraction <50%), 73 had DHF (ejection fraction =>50% with diastolic abnormali- 
ties on Doppler echocardiography), 68 had isolated diastolic dysfunction (DD) and 106 
normal controls. Regional myocardial velocity curves were constructed offline using a 6- 
basal, 6-mid segmental model. Results: The peak regional myocardial sustained systolic 
(Sm) and eady diastolic (Era) velocities were significantly lower in patients with SHF, 
DHF and DD than controls in almost all the myocardial segments. Likewise, the mean 
Sm (SHF < DHF < DD < Controls: 3.3 ± 1.0 < 4.6 ± 1.3 < 5.4 ± 1.0 < 6.3 ± 1.0 cm/s; all p 
<= 0.00t) and mean Em (SHF = DHF < DD < Controls; 3.6 ± 1.2 = 3.9 ± 1.3 < 5.3 ± 1.6 < 
7.2 ± 1.7 cm/s; all p < 0.001) from the six basal segments were decreased in all the dis- 
ease groups. A mean Sm of 4.4 em/s (-2 standard deviation of controls) predicted the 
presence of systolic dysfunction in 92% of patients with SHF, 52% with DHF and 14% 
with DD. Conclusions: Using tissue Doppler imaging, systolic abnormalities were evident 
in patients previously labeled as DHF, and to a much lesser extent, isolated DD. This 
indicates the common coexistence of systolic and diastolic dysfunction in a spectrum of 
different severity in the pathophysiologic process of heart failure. 
1157-155 Prevalence,  Cl in ical  Character is t ics ,  Qua l i ty  of  Life, and 
Prognosis of Patients With Congestive Heart Failure 
and Isolated Diastolic Dysfunction 
Luioi P. Badano. Maria C. AIbanese, Dario Gregori, Paola De Biaggio, Patrizia 
Rozbowsky, Daniela Miani, Claudio Fresco, Paolo M. Fioretti, Cardiovascular Science 
Department, Udine, Italy, IRCAB FOUNDATION, Udine, Italy, 
Background. Prevalence of isolated LV diastolic dysfunction (IDD) has been reported to 
be as high as 1/3 of all chronic congestive heart failure (CHF) cases, with an increasing 
prevalence in the elderly population. However, there is a paucity of prospective data 
about the prevalence and prognosis of IDD in an unselected population of pts admitted to 
hospital with CHF. 
Methods. We prospectively evaluated 179 consecutive Lots admitted in medical depart- 
ments of our hospital for CHF. Among them, 135 (59% males, median age 74 years) 
showed sinus rhythm, and no significant valvulopathy (except heart valve prosthesis or 
secondary mitral regurgitation). CHF was diagnosed using a modification of the Framing- 
ham criteria, and IDD according to the European Study Group on Diastolic Heart Failure 
echo criteria (Eur Heart J 1998;19: 990). Six-month survival of CHF pts was compared 
with that of age- and sex-matched general population living in Udine in 1995. 
Results. Twenty-nine pts (22%) had tDD; 102 (76%) LV systolic dysfunction (i.e. LV ejec- 
tion fraction <45%. There was no difference in age, gender and NYHA functional class 
between pts with IDD or LV systolic dysfunction. Six-month rehospitalisation rate (50% 
and 48%) and median in-hospital length-of-stay during readmissions (10 and 10 days) 
was similar between the 2 groups. Using the Minnesota Living with Head Failure score, 
quality of life was similar between the 2 CHF pt groups both at discharge (39.4 and 34), 
and at 6-month visit (10.4 and 10.4). Six-month survival, adjusted for age and gender, 
was similar between pts with IDD or LV systolic dysfunction (90% and 89.8%, Hazard 
Ratio= 0.99; 95%CI 0.27-3.61), and significantly reduced (Log Rank= 8.58; p<0.001) in 
comparison to that of the general population (Figure). Two pts (7% of pts with LV ejection 
fraction< 45%) did not show any echo evidence of cardiac dysfunction. 
Conclusions: our data show that, using standardized echo diagnostic criteria, prevalence 
of IDD in pts admitted to hospital with CHF seems to be lower than previously reperted. 
CHF pts with IDD showed clinical symptoms, self-perceived quality of life, re-hospitaliza- 
tion rate, and 6-month mortality similar to pts with prevalent systolic dysfunction. 
1157-156 What Is Late Morta l i ty  Af ter  Hospitalization for Heart 
Failure in the Real World? A One-Year Report From the 
Lady Davis Carmel Medical Center Registry 
Rite Yuval, Ita Levin, David A. Halon, Basil S. Lewis, Lady Davis Carmel Medical Center, 
Haifa, Israel School of Medicine, Technion-IIT, Haifa, Israel. 
Background: Heart failure (CHF) is common cause of morbidity and mortality but cur- 
rent prevalence and long-term outcome are largely unknown in general population as 
opposed to pts setocted for clinical trials. 
Patients and Methods: 362 consecutive pts discharged from hospital with clinical CHF 
or suspected CHF (drug treatment compatible with CHF/LV dysfunction) were enrolled in 
CHF registry by prospective screening of internal medical, cardiac, intensive care and 
cardiac surgical departments in 2 hospitals (1 tertiary center with cardiac surgery, 1 refer- 
ral hospital) over 6 week period in each. Survival status at 1 yr was ascertained by tele- 
phone and from governmental records. 
Results: A quarter (90/362, 25%) of CHF pts died within 12 mths, a death rate higher 
than that reported in most recent clinical CHF trials. Pts who died were older (77±10 vs 
75±11 yrs, p=0.03), but death was not predicted by new acute myocardial infarction (AMI) 
or new atrial fibrillation (AF)/paroxysmal AF at time of entry to registry or by presence of 
diabetes mellitus (31/90, 34% vs 74/272, 27%, NS), nor following correction for age and 
sex in stepwise multivariate model. 
Conclusions: In pts hospitalized for CHF or suspected CHF in the real world: 1. Late (12 
mth) mortality was higher than expected. 2. Mortality was higher in older pts. 3. Death 
was not predicted by acute event at entry to database and was marginally but not signifi- 
cantly higher in diabetics. 
Predictors of 1 year mortality 
Vital status (12 Age (yrs) AMIonindex New AF/PAF on IDDM NIDDM 
mths) admission index admission 
Dead (N=90) 77+10 6 (7%) 7 (8%) 7 (8%) 24 (27%) 
Alive (N=272) 75+11 21 (8%) 24 (9%) 21 (6%) 53 (20%) 
p value 0,03 NS NS NS NS 
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1157-157 Impaired Left Ventricular Filltng Predicts Augmented 
Ventilatory Response to Exercise in Patients With 
Chronic Heart Failure 
Faisal AI-Nasser. II1. Mohammed Yousufuddin, Costantinos Dares, Michael Henein, 
Sefan Anker, Massimo Pieopoli, Piotr Ponikowski, heart and lung institute, London, 
United Kingdom. 
Introduction. Augmented ventilator'/response to exercise ( VFJVCO 2 slope) well pre- 
dicts poor prognosis in chronic heart failure (CHF). However, the mechanisms responsi- 
ble for exercise hyperpnea in CHF have not been fully elucidated. The aim of this study 
was to determine the interrelationship between resting ECHO 2D-derived parameters 
and elevated VENCO 2 slope in CHF. Methods and results. In 38 stable CHF patients 
(33 men, 63±8 years, NYHA class fi/lll 26/12) prospective ECHO-2D examination (mean 
end diastolic diameter [EDD]: 68±8 mm, shortening fraction [SF]: 16±7%) followed by 
cardiopulmonary exercise testing (peak oxygen consumption: [peakVO2]: 19.0±6.3 ml/ 
min/kg, VENCO 2 slope 37.6±12.7). VENCO 2 slope correlated with the following 
echocardiographic parameters: short isovolumic relaxation time (IVRT, r=-0.47, 
p=0.005), decreased mitral A wave peak velocity (Ave I, r=-0.44, p=0.006), depressed 
right ventricle long axis function (RV excursion, r=-0.37, p=0.03), and left ventdcular 
restrictive filling pattern (defined as mitral E/A ratio > 1 and deceleration time ~120ms, 
r=0.47, p=0.004). There was no relationship between resting ECHO-2D indices and peak 
VO¢. Twenty (53%) pts with high VENCO 2 i.e. > 34.0) were identified: (table). 
EDD (mm) SF(%) Ave I (m/s) IVRT (ms) RV excursion Restrictive 
(ram) mitral flow 
(%) 
High VENCO 2 68±8 17±7 0.4±0.3** 24±59 12±4" 65* 
(n=20) 
Normal VE/VCO 2 68±8 18±7 0.8±0.3 50±25 17±4 29 
(n=18) 
Mean ± SD, *p<0.05, **p<0.01 high vs normal VE/VCO2Conclueion: In CHF impaired 
left ventricular filling pattern and depressed right ventricle long axis function may be 
important factors responsible for augmented ventilatory response to exercise. 
1157-158 Efficacy and Tolerability of Carvedllol in DiabeUc 
Patients With Chronic Heart Failure 
Yule Ten, Eugene Kotlyar, Anne M. Keegh, Christopher Hayward, Peter S. Macdonald. St 
Vincent's Hospital Sydney, Australia, Victor Chang Cardiac Research Institute, Sydney, 
Australia. 
Background: The benefits of beta blockers (BB) in patients with chronic heart failure 
(CHF) are well established, however, there is limited data on the impact of BB in diabetic 
CH F patients, a subgroup in whom BB have been considered relatively ocntra-indicatad. 
The aim of this study was to compare the efficacy and tolerability of the BB, carvedilol in 
diabetic and non-diabetic CHF patients. 
Methods: A retrospective analysis was conducted on 505 consecutive patients with CHF 
(434 men, 71 women) aged 55+13 years who were commenced on carvedilol between 
February 1996 and May 2001. Ninety-three patients (18%) had a history of diabetes mel- 
litus (DM group). Patients were reviewed at 3, 6, 12, 18 and 24 months then annually. 
Vital signs, NYHA functional class, 6 minute walk distance (6MWD), carvedilol dose and 
echocardiographic measurements of LV dimensions (LVEDD and LVESD) and fractional 
shortening (FS) were recorded at each visit. In addition, survival and non-fatal adverse 
events were recorded. 
Results: There were no significant differences between the DM and non-DM groups at 
baseline with respect to age, sex, duration of CHF, heart rate, diastolic blood pressure, 
serum Na+ and creatinine, drug therapy, NYHA class, LV dimensions and function. The 
DM group were significantly heavier, had lower 6MWD, and higher systolic blood pres- 
sure at baseline. A higher percentage of diabetics had ischemic heart disease (54% v 
37%, p=0.007). During a mean follow up of 32+18 months, 22% of the DM group died, 
12% underwent heart transplantation (HTx) and 11% withdraw from carvedilol due to 
adverse events. In comparison, 19% of the non-DM group died, 9% underwent HTx and 
18% were withdrawn from carvedilot due to adverse events (all p=ns compared with DM 
group). Mean maintenance carvedilol doses were 42+2 and 39+3 rag/day for DM and 
non-DM groups (p=ns). At 24 months, NYHA class and 6MWD improved significantly, 
LVEDD fell by 3.1±0.5 mm, LVESD by 4.9±0.6 mm and FS rose by 3±1% (all p < 0.0001 
versus baseline, n=226), with no significant differences between the DM and non-DM 
groups. 
Conclusion: The tolerability, clinical outcomes and beneficial effects of carvedilol on LV 
remodelling are similar in diabetic and non-diabetic CHF patients. 
1157-159 Is Additional Neurohormonal Antagonism Useful in 
Patients With Severe Chronic Heart Failure Already 
Receiving a Combination of Neurohormonal 
Antagonists? Results of the COPERNICUS Study 
Henrv Krum. Paul Mohacsi, Hugo A. Katus, Michal Tendera, Jean L. Rouleau, Michael B. 
Fowler, Andrew J. Coats, Ellen B. Roecker, Milton Packer, for the COPERNICUS Study 
Group., Monash Universi~ Prahran Victoria, Australia. 
Background. The results of the VaI.HeFT study suggested that broad based neurohor- 
monal blockade may have deleterious effects in patients with heart failure (HF), but this 
hypothesis has not been evaluated in other trials. 
Methods. The 2289 patients with severe HF in the COPERNICUS trial were randomized 
to placebo (PBO) or carvedilol (CRV), which were added to diuretics and an ACE inhibi- 
tor (+ digitalis) for up to 29 months. Of these patients, 445 were also on spironolactone at 
baseline and thus received 3 neurohormonal antagonists if they were randomized to 
CRV. Compared with those not on spironolactone, patients on spironolactone had a 
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lower blood pressure and serum Na and were more likely to have had a recent HF hospi- 
talization (all P < 0.001). Results. Shown below are 1-year Kaplan-Meier ates and Cox 
model hazard ratios (CRV:PBO): 
Spironolactone No Spironolactone 
PBO CRV Hazard PBO(n=908) CRV (n=936) Hazard ratio 
(n=225) (n=220) ratio 
All-cause 19.1% 11.4% 0.65 18.4% 11.3% 0.65 
mortality 
Death or 39.3% 26.3% 0.63 37.5% 25.4% 0.70 
hospitalization 
for worsening HF 
Death or 41.6% 29.1% 0.61 41.6% 30.4% 0.75 
cardiovascular 
hospitalization 
Death or any 47.2% 38.4% 0.76 53.3% 42.1% 0.76 
hospitalization 
CRV reduced the risk of a major clinical event in patients on spironolactone to an extent 
similar to that seen in patients not on spironolactone. 
Conclusion. These data indicate that the morbidity and mortality of patients with severe 
HF receiving drugs that interfere with more than one neurohormonal target can be 
reduced substantially with further neurohormonal antagonism (with CRV). 
1157-160 Beta-Blocker Utilization in Heart Failure Patlenta: 
Experience From a Heart Failure Clinic 
Ritash Gueta, W.H. Wilson Tang, James B. Young, Cleveland Clinic Foundation, 
Cleveland, Ohio. 
Background: Beta blockers (BB) reduce mortality in heart failure (HF) patients. Though, 
well tolerated in clinical trials, utilization rates in clinical settings have not been studied. 
Methods: Retrospective analysis of 500 consecutive HF patients presenting to a HF 
clinic between 3/01 to 5/01 (mean age 61, 69% males, 53% ischemic, mean LVEF 27%). 
Chi-square test was utilized for subgroup analysis. 
Results: 75% of patients had been given a BB trial and 69% were currently on BB. The 
use of BB was more in moderate (LVEF 20 - 40, n=236) compared to mild (LVEF >40, n 
= 92) and severe (LVEF <20, n =141) HF (73% vs. 60% and 65%, p=0.04). BB use also 
decreased with worsening NYHA class of HF symptoms (I 76%, II 72%, III & IV 60%, 
p=0.01). No difference in BB use by gender was seen (68% in males vs. 71%, p=0.5). 
Discontinuation rate was 6.8% and was not influenced by NYHA class (p=0.3). Down 
titration was required in 5.2%. Side effects leading to stopping or down titration, included 
dizziness (3.2%), fatigue (2.8%), hypotension (2.6%), bradycardia (2.0%), and others 
(1.4%). A contraindication could be identified in 44% of patients never tried on BB with 
respiratory disease being the most common in 33%, uncompensated state in 7%, A-V 
block in 1% and hypotansion in 1.6%. Subgroup of diabetics had lower BB use than non 
diabetics(60% vs 73%, p=0.02) with more contraindications (36% vs. 18%, p < 0.01 ) and 
worse NYHA class (p= 0.03) though LVEF was similar (p=0.5). Trend towards lower BB 
use was seen in elderly patients (age >74) than younger patients (61% vs. 71%, p=0.06) 
but there was no difference in rate of contraindication to BB(29% vs. 23%, p= 0.1 ). 
Conclusion: High utilization rates for BB (69% current usage) can be achieved with an 
aggressive approach to initiating BB therapy. Respiratory diseases are the most common 
reason of not initiating BB therapy. Diabetics and elderly patients are less likely to be on 
BB. Diabetics tend to have more contraindications to BB and worse NYHA class than 
non diabetics, which may explain lower use of BB in them. Eldedy patients do not show 
this trend and lower use in this group needs further investigation. 
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1158-146 Phosphoramidan Ameliorates the Functional Sequelae 
of Experimental  Chronic Chagasic Cardiomyopathy 
Madhulika Chandre, Herbert B. Tanowitz. Vitally Shtufln, Jamshid Shirani, Albert Einstein 
College of Medicine, Bronx, New York. 
Background. Trypanosoma crozi, the etiologic agent of Chagas' disease, is an important 
cause of chronic cardiomyopathy. Coronary microvascular spasm, in part mediated by 
endothelin-1, appears to play a significant role in the pathogensis of experimental chronic 
chagasic cardiomyopathy. Aim. We sought to assess if the administration of an endothe- 
lin inhibitor, phosphoramidan, could influence the severity of cardiomyopathy in mice 
infected with T. cruzL Methods. Therefore we infected cdl mice (n=21) with 104 trype- 
mastigotes of the Brazil strain of "K cruzi. Of these, 8 were treated with phosphoramidan. 
An additional 8 uninfected littermatas ewed as controls (C), 3 of which received phos- 
phorarnidan. All mice (n--29) survived and were evaluated at 150 days post infection by 
transthoracic echocardiography. Left ventricular (LV) end diastolic diameter (EDD), rela- 
tive wall thickness (RW'F), and fractional shortening (FS) were measured. Right ventricu- 
lar (RV) size was assessed semi-quantitatively on a scale of 0-3. Results. There was no 
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effect of phosphoramidan on LV EDD, RWT, FS or RV in uninfected (C) mice. Infected, 
untreated mica (INF) had increased LV EDD (3.2±0.1 v 2.8±0.1mm, p<0.05), along with 
reduced FS (39±2 v 57±1%, p<0.05) and RWT (0.4±0.0 v 0.5±0.0, p<0.05), compared 
with C. Treatment with phosphoramidan reduced the magnitude of these changes, such 
that the infected, phcaphoramidan treated mica (INF+P) had no significant differences in 
LV EDD (2.9±0.1 v 2.8±0.1mm), RWT (0.5±0.1 v 0.5±0.1), and FS (57±2 v 50¢4%) com- 
pared with C mice. Similarly, RV was larger in INF compared with both C and INF+P mice 
(2.1¢0.3 ,) 1.5±0.4, INF v INF+P respectively, p<0.01). Conclusion. These data indicate 
that phosphoramidan ameliorates the functional sedulae of experimental chronic cha- 
gasic cardiomyopathy. 
1158-147 Molecular Epidemiology of Cardiac Actin Gene 
Mutations in Dilated Cardlomyopathy 
Ronald Zoltv, G. Passarino, M. R. Taylor, A. Moss, L. Mastroni, M. R. Bristow, UCHSC, 
Denver, Colorado, Stanford University, Palo Alto, California. 
Background: Dilated cardiomyopathies (DCM) are characterized by a large vantricular 
dilatation and impaired systolic function. There is a strong genetic component in DCM, 
estimated to be present in approximately 20-30percent of cases. Mutations in axons 5 
(Arg312His) and 6 (Glu361Gly) of cardiac actin gene (ACTC) have been reported in two 
families with DCM. Methods: In order to evaluate prevalence and characteristics of 
ACTC gene mutations in DCM, 62 patients from different ethnic backgrounds were stud- 
ied: 17 with sporadic DCM, 45 with familial DCM (belonging to 31 unrelated families). 
Two patients with ischemic heart disease were used as controls. Genomic DNA was 
extracted from blood or explanted heart tissue using standard procedures. PCR products 
were generated from all 6 exons of the ACTC gene, allowing the inclusion of the exon,' 
intron boundaries. Mutation analysis of all 6 axons was performed using denaturing high 
performance liquid chromatography (DHPLC) and sequence analysis. Results: No muta- 
tion was found in any of the six ACTC exons. A single nuclectide pelymorphism was 
detected by DHPLC, and confirmed by sequence analysis in intron 5 (C-62T). Conclu- 
sions: ACTC mutations do not seem to be associated with DCM in our large population of 
familial and sporadic DCM. ACTC mutations appear to be infrequently associated with 
DCM 
1158-148 Noninvseive Asselmment of Coronary Flow Reserve 
Impairment in Patients With Systemic Sclerosis 
Roberta Montisci. Paolo Colonna, Massimo Ruscazio, UJun Chen, Carlo Caiati, Pietro 
Gareu, Giuseppe Passiu, Alassandra Vacca, Alessandro Mathieu, Sablno Ilicato, 
Department of Cardiovascular and NeuroL Sciences, Cagliari, italy, Institute of 
Rheumathology, Cagliari, Italy. 
Background. Systemic sclerosis (SSc) is a chronic connective tissue disorder of 
unknown etiology, characterized by cutaneous and visceral tissue fibrosis with arteitolar 
and capillary ischemic dysfunction. The pathogenesis of the cardiac lesion in SSc is con- 
troversial, but the primary disorder of microvasculature with diffuse artsriolar and capil- 
lary lesions could precede any fibrosis, thus causing ischemic disorder to the head. CFR 
is used to evaluate coronary microcirculation, and has been already employed to investi- 
gate myocardial microcirculation impairment in SSc. Previous invasive studies have 
demonstrated that coronary flow reserve (CFR) is impaired in patients (pts) with 
advanced SS and cardiac involvement. We tested the hypothesis that CFR can be early 
impaired in patients with systemic sclerosis without cardiac involvement and whether 
CFR impairment is correlated to the cutaneous subset. 
Methods. We studied 26 patients with SSc without clinical evidence of heart disease, (14 
with diffuse form and 12 with localized form of SSc) and 22 control group patients, 
matched in age and gender. We evaluated CFR in the left anterior descending coronary 
artery (LAD) with a new non-invasive method : contrast (Levovist) enhanced transtho- 
racic Doppler (CEE-TTE) during adenosine infusion. The pulsed wave Doppler of blood 
flow velocity was recorded in the LAD at rest and after maximum vasodilaflon by adenos- 
ine infusion (140 mcg/Kg/min in 5 minutes). 
Results: In patients with SSc, without clinical evidence of heart disease, CFR was 
impaired (2.65:t:0.63 vs 3.29~0.52 in controls, p < 0.0005). A significantly, greater per- 
centage of SSc patients had reduction of (_< 2.5) CFR compared to controls ( 48% vs 
4.5%, p=0.003). Left ventricular mass and ejection fraction were not statistically different 
in the two groups. A non-significant trend between mean CFR and the severity and dura- 
tion of the disease was also observed. 
Conclusion. in this cross-sectional study we demonstrated that CFR is early reduced in 
patients with SSc and seems to be correlated to the extension of the cutaneous subset of 
the disease. A reduction of CFR could be an early sign of cardiac involvement in sys- 
temic sclerosis. 
1158-149 Clinical Course of Dilated Cardiomyopathy in 
Asymptomatic Patients Long-Term Treated With Beta- 
Blocking Agents: The Heart Muscle Disease Registry of 
Trieste 
Andrea Di Lenarda, Gastone Sabbadini, Gererdina Lardieri, Mauro Driussi, Elisa Camiel, 
Laura Vitali Serdoz, Stafano Pangher, Gianfranco Sinagra, Department of Cardiology, 
Trieste, Italy, Department of Medicine and Geriatrics, Trieste, Italy. 
No conclusive data are available on long-term effects of adding a beta-blocker (BB) to 
ACE-inhibitor (ACE-I) therapy in asymptomatic patients with dilated cardiomyopathy 
(DC). 
Among 447 DC patients consecutively enlisted in the Heart Muscle Disease Registry of 
Trieste between 1986 and 2000, 307 (68.7%) had HF symptoms (NYHA II-IV, Group 1) 
while 140 (31.3%) were asymptomatic (NYHA I, Group 2) at enrolmect, in Group 2, a 
previous history of HF was present in 71 patients (50.7%)(Group 2a) and absent in 69 
(49.3%)(Group 2b). 
